Even bigger gaps in care seen for people living in low-income and lower middle-income countries<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, Feb. 15, 2022 (HealthDay News) — Treatment coverage for major depressive disorder (MDD) continues to be low in many parts of the world, particularly in low-income and lower middle-income countries, according to a systematic review and Bayesian meta-regression analysis published online Feb. 15 in PLOS Medicine<\/em>.<\/p>\n Modhurima Moitra, Ph.D., from the University of Washington in Seattle, and colleagues conducted a systematic literature review to estimate MDD treatment coverage and gaps by location and treatment type between 2000 and 2019.<\/p>\n Based on 149 studies, treatment coverage for health service use ranged from 51 percent in high-income locations to 20 percent in low-income and lower middle-income locations, while treatment coverage for mental health service ranged from 33 percent in high-income locations to 8 percent in low-income and lower middle-income countries. Rates of minimally adequate treatment ranged from 23 percent in high-income countries to 3 percent in low-income and lower middle-income countries.<\/p>\n “Treatment coverage for major depressive disorder continues to be low globally, with many individuals failing to receive a level of care consistent with practice guideline recommendations,” a coauthor said in a statement. “This highlights the need to reconsider the availability of appropriate care and facilitators of treatment as we respond to the large burden imposed by this disorder.”<\/p>\n